ArticleOncology letters2025
Cancer-associated mesenchymal stem cell exosomes facilitate non-small cell lung cancer cell viability and invasiveness by delivering miR-182 in a FBXW7-related AKT and ERK-dependent pathway.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Exosomes as Pivotal Mediators of Tumor-Immune Communication: Implications for Immunotherapy and Liquid Biopsy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated mesenchymal stem cells (CA-MSCs) modulate the tumor microenvironment and promote tumor progression. The present study aimed to investigate the effects of CA-MSCs, CA-MSC-derived exosomes and CA-MSC exosome-derived microRNA (miR)-182 on non-small cell lung cancer (NSCLC) cell viability and invasiveness. CA-MSCs were established by treating MSCs with supernatant from NSCLC cells. Then, two NSCLC cell lines (A549 and H1299) were treated with CA-MSCs, CA-MSCs + GW4869 (inhibits exosomes) and CA-MSC exosomes. Additionally, miR-182 inhibitor was added to CA-MSCs and the related exosomes were used to treat NSCLC cells. Furthermore, miR-182 mimic and F-box and WD repeat domain containing 7 (FBXW7) overexpression vector were used to treat NSCLC cells. The results indicated that CA-MSCs promoted NSCLC cell viability and invasiveness and inhibited cell apoptosis, an effect that was attenuated following GW4869 treatment. The CA-MSC exosomes also enhanced NSCLC cell viability and invasiveness while inhibiting cell apoptosis. In addition, CA-MSC exosomes elevated miR-182 expression in NSCLC cells. Subsequently, CA-MSC exosomes with miR-182 expression knockdown exhibited a weakened effect on NSCLC cell viability, apoptosis and invasiveness compared with control CA-MSC exosomes. Direct miR-182 mimic transfection enhanced NSCLC cell viability and invasiveness and inhibited cell apoptosis, an effect that was attenuated by transfection with the FBXW7 overexpression vector. Furthermore, miR-182 negatively regulated and sponged FBXW7 expression in NSCLC cells. Finally, treatment of the cells with miR-182 mimic increased the phosphorylated (p-)AKT and p-ERK1/2 expression levels, while treatment with the FBXW7 overexpression vector decreased these levels in NSCLC cells. In summary, CA-MSCs facilitated NSCLC viability and invasiveness via transmitting exosomal miR-182 in a FBXW7-related AKT and ERK-dependent pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.